Tabunda, Gemalyn .
HRN: 11-30-00 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/12/2023
CEFUROXIME 500MG (TAB)
06/12/2023
06/19/2023
PO
500mg
BID
Thickly MSAF
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes